Know Cancer

forgot password

Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas

Phase 2
18 Years
Open (Enrolling)
Pituitary Macroadenoma

Thank you

Trial Information

Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas

Inclusion Criteria:

- Pathological or radiographic diagnosis of a pan-invasive pituitary macroadenoma

- Pan-invasive for the purposes of the protocol will be defined as meeting each of the
following 2 major criteria: (1). tumor volume greater than 20 cc at enrollment, and
(2). suprasellar extension. In addition, a pan-invasive tumor must meet any one of
the following 3 minor criteria, a) unresectable tumor invasion into a cavernous
sinus, b) bone or bone marrow invasion into the clivus or temporal bones, or c) tumor
extension in any direction unlikely to be completely removed by specifically a
transphenoidal surgical approach.

- Patients who meet the two major criteria above (1 and 2) and are medically inoperable
for tumor resection (due to confounding co-existing medical problems) are eligible
without meeting any of the three minor criteria (a, b, or c).

- Patients should be immediately threatened for vision loss or other significant
neurological impairment directly related to tumor mass effect. As such, all patients
enrolled would likely benefit from tumor response (shrinkage).

- Patients must have visible tumor on imaging studies (MRI or CT)

- The patient's Zubrod performance status must be 0-3.

- Patients must be at least 18 years of age.

- Mandatory Imaging Studies: Must be done 45 or fewer days prior to :

MRI or CT scan of the brain including the entire skull base and all areas of tumor

Exclusion Criteria:

- Patients who are unable to undergo general anesthesia

- Patients who are unable to undergo placement of a stereotactic head frame

- Patients who are unable to provide informed consent

- Patients who are pregnant or nursing

- Patients with severe kidney dysfunction

- Patients who have contraindications to MRI, such as implanted pacemaker device

- Patients with diagnosis of pituitary carcinoma

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Partial response (reduction in 30% of tumor volume) or greater response within 12 months from the implant procedure.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Robert Timmerman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Texas Southwestern Medical Center


United States: Institutional Review Board

Study ID:

STU 042011-075



Start Date:

October 2011

Completion Date:

December 2016

Related Keywords:

  • Pituitary Macroadenoma
  • pituitary gland



University of Texas Southwestern Medical CenterDallas, Texas